Overview
The evidence base for 5-Amino-1MQ can span preclinical work, early human data, and—where applicable—larger clinical trials. The strength and maturity of that evidence determine how confidently clinicians and researchers talk about its effects.
Key evidence themes
- Preclinical models exploring mechanisms and proof-of-concept.
- Early human or pilot data, if available.
- Larger controlled trials for molecules with formal indications.
Context and caveats
When reviewing literature on 5-Amino-1MQ, it is important to consider study design, endpoints, sample size, and duration, as well as how closely study populations match real-world use. Marketing narratives frequently move faster than rigorous evidence.
Sport & Anti-Doping Warning
5-amino-1MQ is a small-molecule NNMT inhibitor marketed in some wellness and physique circles; as an unapproved drug, it falls into the general S0 category of non-approved substances under the World Anti-Doping Code.
- >Background on 5-amino-1MQ as an experimental metabolic agent
- >WADA guidance that non-approved drugs are prohibited under S0
Even when not named explicitly on the Prohibited List, experimental metabolic drugs like 5-amino-1MQ are captured by the S0 'non-approved substance' rule.